Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Asia, China and Canadian Stocks » LOR (lorus therapeutics)

 - UBBFriend: Email this page to someone!    
Author Topic: LOR (lorus therapeutics)
kiknazz
Member


Rate Member
Icon 1 posted      Profile for kiknazz     Send New Private Message       Edit/Delete Post   Reply With Quote 
Mentioned this stock in an earlier thread...

Volume picking up, broke through resistance @ 1.22...

In @ 1.13


Posts: 136 | From: canada | Registered: May 2003  |  IP: Logged | Report this post to a Moderator
kiknazz
Member


Rate Member
Icon 1 posted      Profile for kiknazz     Send New Private Message       Edit/Delete Post   Reply With Quote 
Nice close today @1.38.

Maybe news coming... let's hope.

Volume was outstanding.


Posts: 136 | From: canada | Registered: May 2003  |  IP: Logged | Report this post to a Moderator
kiknazz
Member


Rate Member
Icon 1 posted      Profile for kiknazz     Send New Private Message       Edit/Delete Post   Reply With Quote 
News out....

Lorus Therapeutics announces third clinical trial with GTI-2040 in cooperation with the U.S. National Cancer Institute

07:01 EDT Monday, September 15, 2003


- GTI-2040 in combination with docetaxel for the treatment of lung
cancer -

TSX: LOR
OTC BB: LORFF

TORONTO, Sept. 15 /CNW/ - Lorus Therapeutics announced today that approval has been obtained from Health Canada for initiation of a clinical trial of GTI-2040 in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC), as part of a Phase II clinical program of GTI-2040 in collaboration with the U.S. National Cancer Institute (NCI). The study will be conducted under the direction of Dr. Natasha Leighl at Princess Margaret Hospital in Toronto, a leading clinical and research centre for cancer.

Additional leading oncology centres and investigators participating in this study include the Ottawa Regional Cancer Centre (Dr. Scott Laurie), Hamilton Regional Cancer Centre (Dr. Peter Ellis), and London Regional Cancer Centre (Dr. Mark Vincent).

The study is supported by the Cancer Therapy Evaluation Program (CTEP), an NCI agency that is providing both program coordination and financial sponsorship as part of its mission to support the development of novel anticancer agents.

"Inclusion of lung cancer in the GTI-2040 clinical program in cooperation with the U.S. NCI and leading Canadian oncology clinical research centres is an excellent opportunity to apply our strategy of combining GTI-2040 with established chemotherapeutic regimens without increasing the toxicity profile," said Dr. Jim Wright, chief executive officer, Lorus. "We are pleased to be working with leading oncologists on the development of GTI-2040 in this indication."

Advanced NSCLC, the most common form of lung cancer, is incurable and median survival with current treatments ranges from 8 to 10 months. Based on National Cancer Institute of Canada and American Cancer Society statistics for 2002, it is estimated that 189,000 North Americans will be diagnosed with lung cancer and 173,000 will die from the disease this year.

While advancements in combination therapies have improved the one year survival rate in lung cancer patients from 25 per cent to greater than 30 per cent, there is a clear need for novel combination treatments to further improve lung cancer outcomes.

Lorus also recently announced the expansion of GTI-2040 into two additional NCI-sponsored studies. One in Acute Myeloid Leukemia is being conduced at Ohio State University Medical Center in Columbus, Ohio under the direction of Dr. Guido Marcucci. Dr. Helen Chew of the University of California Davis Cancer Center is conducting the second study, in advanced breast cancer. The NCI is financially sponsoring this series of Phase II clinical trials to investigate the safety and efficacy of GTI-2040 in six different cancer indications.

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, a malignant determinant that is elevated in a wide range of tumors and which can cooperate with a variety of other cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 was chosen for combination with docetaxel, an established agent for treatment of lung cancer, based on preclinical data providing significant activity against NSCLC as a single agent, potential synergy with taxanes in preclinical models, and low toxicity observed as a single agent in a Phase I clinical trial.


Posts: 136 | From: canada | Registered: May 2003  |  IP: Logged | Report this post to a Moderator
VIP
Member


Rate Member
Icon 14 posted      Profile for VIP     Send New Private Message       Edit/Delete Post   Reply With Quote 
Please tell me why they trade on TSX and on OTCBB?

do you know why LOR traded on both EXCHANGE.


need to know and plus on OTC, it has 5 symbols LOFRR .. i dont like buying with 5 words symbol stock......
something is not right.

what do u think...


Posts: 393 | Registered: Jul 2003  |  IP: Logged | Report this post to a Moderator
kiknazz
Member


Rate Member
Icon 1 posted      Profile for kiknazz     Send New Private Message       Edit/Delete Post   Reply With Quote 
HI VIP...

I'll check it out...

You meant"LORFF" instead of lofrr...lol


Posts: 136 | From: canada | Registered: May 2003  |  IP: Logged | Report this post to a Moderator
VIP
Member


Rate Member
Icon 14 posted      Profile for VIP     Send New Private Message       Edit/Delete Post   Reply With Quote 
yeah LORFF.....

please check it out..

why they trade on both TSX and otc?

??????????


Posts: 393 | Registered: Jul 2003  |  IP: Logged | Report this post to a Moderator
kiknazz
Member


Rate Member
Icon 1 posted      Profile for kiknazz     Send New Private Message       Edit/Delete Post   Reply With Quote 
News for Lorus...

Lorus licenses NC 381 and library of clotrimazole analogs to Cyclacel Limited

--------------------------------------------------------------------------------
Advertisement

Hide advertisement


--------------------------------------------------------------------------------


07:01 EDT Wednesday, September 24, 2003

TORONTO, Sept. 24 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus"), a biotechnology company focused on the development of novel cancer treatments, and its subsidiary, NuChem Pharmaceuticals Inc. ("NuChem") and Cyclacel Limited, ("Cyclacel") a UK-based biopharmaceutical company, announced they have entered into an exclusive worldwide license agreement for the development and commercialization of Lorus' pre-clinical compound NC 381. The agreement extends to other drug candidates that Cyclacel may identify from a library of clotrimazole analogs licensed by NuChem from Harvard Medical School in 1997.

Under the terms of the agreement, Lorus will receive upfront fees of US $400,000 and milestone payments, which assuming all milestones are achieved, will total approximately US $11.6 million for NC 381, and similar milestone payments for each of any other compounds developed from the compound library. In addition to these payments, Lorus will receive royalties based on product sales. Cyclacel will be responsible for all future drug development costs.

"Lorus, in collaboration with the U.S. National Cancer Institute, has identified the promise of NC 381 and several other compounds for the treatment of cancer," said Dr. Jim Wright, CEO of Lorus. "We are pleased with this partnership with Cyclacel, a company that has world-class expertise in understanding cell cycle arrest mechanisms. We believe Cyclacel has scientific and product expertise pivotal to the development of drugs such as NC 381."

Dr. Wright added: "Lorus is focusing its resources on the development of its advanced clinical programs and its other pre-clinical technologies, as it moves its lead products, Virulizin, GTI-2040 and GTI-2501 through the clinic."

Spiro Rombotis, CEO of Cyclacel said, "The agreement with Lorus validates Cyclacel's global reputation as a leader in cell cycle chemistry and biology. We are pleased to be in partnership with an innovative cancer therapeutics company like Lorus and look forward to a mutually-beneficial relationship."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward- looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.


Posts: 136 | From: canada | Registered: May 2003  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share